Please login to the form below
opioids
This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
The bad reputation was attributed to, most notably, the ongoing opioid litigation against a number of pharma companies and ongoing scrutiny over medicine prices. ... According to Gallup: “The industry's rating likely will not recover until its role in
Latest news
-
UPDATED: J&J's $8bn Risperdal judgment reduced to $6.8m
J&J has been hit with serial lawsuits claiming damages in the last few years, with cases involving asbestos in talc, hip replacement and vaginal mesh products, and opioid drugs all ... Last August, the company was ordered to pay $572m following a legal
-
FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
In England and Wales, prescriptions for opioid medicines have risen from around £14m in 2008 to around £23m in 2018. ... Last year, Health Secretary Matt Hancock announced measure to counteract possible misuse of these drugs, by introducing mandatory
-
Nektar’s opioid analgesic slammed with FDA panel rejection
High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Although the rejection is a blow to Nektar, the opioid painkiller had already been somewhat
-
The year in review
2020. And no review of healthcare in 2019 would be complete without mentioning the opioid crisis.
-
UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
This includes the ongoing opioid crisis and litigation, drug contaminations in major products and the outbreak of a lung illness thought to be caused by certain electronic vaping products.
More from news
Approximately 29 fully matching, plus 145 partially matching documents found.
Latest Intelligence
-
The transatlantic opioid crisis
There’s some evidence to suggest similar transgressions in the UK with opioids. ... In another case, a single GP had ten patients addicted to synthetic opioids.
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
European operations, said the company is close to new registrations in Europe for opioid addiction products. ... be fully dedicated to helping patients, doctors and communities dealing with opioid addiction.’.
-
Trust: the ultimate elevator
This is particularly apparent for the traditional ‘big pharma’ sector – shaken by scandals such as pricing, manipulative patent litigation and a rampant opioid epidemic.
-
Drug launches to watch in 2019
About 2.5m people have been diagnosed with opioid dependence in the US, and almost one million are receiving treatment. ... New to the opioid dependence treatment market this year is CAM2038, marketed by Camurus, a company headquartered in Lund, Sweden.
-
Pharma deals continue to slide
These companies have been running out of cash and have had to do deals to stay alive. Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase
More from intelligence
Approximately 2 fully matching, plus 22 partially matching documents found.
Latest appointments
-
Egalet appoints Stan Musial as CFO
s pipeline of abuse-deterrent opioids are nearing phase III.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018. ... The two-day event succeeded in delivering what IOTOD is well known for: expert
-
IOTOD: Improving Opioid Dependence Outcomes
IOTOD’s future. The IOTOD educational initiative perpetually aims to provide the most up-to-date information in the field of opioid addiction. ... in opioid addiction and gain valuable insight on some of the most controversial topics in the field.
-
"Legal highs" ruling leaves illegal labs laughing
So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. . ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse. .
-
Research Partnership has published a new Living with Chronic Pain market report for 2016
At least 60% of the patients surveyed are currently prescribed long acting opioids (LAOs).
-
How digital content is helping physicians curb the opioid abuse epidemic
using their state’s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... topic. And there’s plenty of evidence that this approach works—having a measurable and almost immediate impact on how physicians
More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.
Featured jobs
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
-
Consultant
-
competitive salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
Salary TBC
Subscribe to our email news alerts
- Moving annual total (MAT)
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- Immuno-oncology, personalised medicine continues to drive pharma sector
- FDA delays decision on Intercept's NASH drug by three months
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
